Synergic antitumoral effect of an IGF-IR inhibitor and trastuzumab on HER2-overexpressing breast cancer cells.
about
Autophagy facilitates the development of breast cancer resistance to the anti-HER2 monoclonal antibody trastuzumabSmall is beautiful: insulin-like growth factors and their role in growth, development, and cancert10c12 conjugated linoleic acid suppresses HER2 protein and enhances apoptosis in SKBr3 breast cancer cells: possible role of COX2.Personalizing HER2-targeted therapy in metastatic breast cancer beyond HER2 status: what we have learned from clinical specimensThe insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study.ErbB2 enhances mammary tumorigenesis, oncogene-independent recurrence and metastasis in a model of IGF-IR-mediated mammary tumorigenesis.Treatment with a combination of the ErbB (HER) family blocker afatinib and the IGF-IR inhibitor, NVP-AEW541 induces synergistic growth inhibition of human pancreatic cancer cells.Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer.Insulin-like growth factor-1 receptor signaling increases the invasive potential of human epidermal growth factor receptor 2-overexpressing breast cancer cells via Src-focal adhesion kinase and forkhead box protein M1.Human pancreatic cancer stem cells are sensitive to dual inhibition of IGF-IR and ErbB receptors.Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer.Pharmacological strategies to overcome HER2 cross-talk and Trastuzumab resistance.Deciphering the role of insulin-like growth factor-I receptor in trastuzumab resistance.New developments in the treatment of HER2-positive breast cancerSurvival of HER2-Positive Breast Cancer Cells: Receptor Signaling to Apoptotic Control Centers.Growth factors as active participants in carcinogenesis: a perspective.Advances in novel drug delivery strategies for breast cancer therapy.Hitting multiple targets in HER2-positive breast cancer: proof of principle or therapeutic opportunity?Biological insights into effective and antagonistic combinations of targeted agents with chemotherapy in solid tumors.Insulin-like growth factor receptor (IGF-1R) in breast cancer subtypes.Identification of a SOX2-dependent subset of tumor- and sphere-forming glioblastoma cells with a distinct tyrosine kinase inhibitor sensitivity profile.Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours.Effect of multikinase inhibitors on caspase-independent cell death and DNA damage in HER2-overexpressing breast cancer cells.Treatment of biliary tract cancer with NVP-AEW541: mechanisms of action and resistance.IGF-1R peptide vaccines/mimics inhibit the growth of BxPC3 and JIMT-1 cancer cells and exhibit synergistic antitumor effects with HER-1 and HER-2 peptides.Radiological response in an incidental meningioma in a patient treated with chemotherapy combined with CP-751,871, an IGF-1R inhibitor.Relevance of insulin-like growth factor 1 receptor gene expression as a prognostic factor in non-small-cell lung cancer.Diagnostic utility of mammaglobin and GCDFP-15 in the identification of primary neuroendocrine carcinomas of the breast.
P2860
Q27346475-86E0C679-2522-4EF1-B5CB-234873FFA770Q30395770-BED08782-E89F-45CF-B706-826AC9513210Q30862407-064EC236-7C48-4268-8F29-D5570106294AQ33735413-881195D5-92BA-41EA-B845-591A0DC2AC6BQ34059707-40471912-0D8A-4205-98BA-CBA48249F06DQ34133760-952CBC66-0A6B-49DD-8644-8319314E6B88Q34569071-106110B5-DB7C-43AE-9ECC-B69D8B15C40DQ34664129-8336EAEE-621A-4385-8B32-FF26FF5F21D3Q34946846-AD0CB6B5-0357-4E96-8DF0-6E91114036E2Q35494483-5E70275D-67F2-4649-BB7D-4C6C391380C6Q35653820-BDD1406E-0099-4C1B-9591-46059B5E7A36Q35803226-51AE4DD1-0EDB-493D-ADDB-5B35F2A5078AQ36102124-2FB90044-A4C0-49F2-A573-87DE319A0FF9Q37016382-5F092279-4FBE-40CE-9B42-9EFBE3512818Q37194856-AC34F0BC-136B-432D-A282-7C3C7FCE8C6FQ37676697-4DCA8F1B-0558-4D52-AD55-D031EB49E3A7Q37777142-5AE3F138-4DC5-4275-A771-D1EA9178316BQ37826199-5A2E284F-1438-4F45-B0F1-577C479B941EQ38171330-7DC8AD6A-6DE4-4940-B343-501DEBAB9533Q38410339-0E4AFBBF-688D-48DE-B409-F112D8C6FD47Q38790973-AB1924C2-A4CB-4D8A-99D3-616BFB90B4F4Q39250672-32BB32F4-E1F7-4E44-8CEE-D559D75B9D81Q39660788-772B76D9-F175-459F-A489-E2E056C672B7Q39753305-B64A8865-2B23-4911-A2D2-3CC5F2DC38F9Q42107855-785F0132-D929-4E33-9E26-E92A50AA75A5Q43080280-2041B8DE-7611-4972-8727-62FF3369A2DDQ44636888-6950C45D-3D00-4F3C-92A8-63951C2CA7F8Q54638064-5B0AA4E8-37BD-41DD-A08F-1E0F5430A5DD
P2860
Synergic antitumoral effect of an IGF-IR inhibitor and trastuzumab on HER2-overexpressing breast cancer cells.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Synergic antitumoral effect of ...... xpressing breast cancer cells.
@en
Synergic antitumoral effect of ...... xpressing breast cancer cells.
@nl
type
label
Synergic antitumoral effect of ...... xpressing breast cancer cells.
@en
Synergic antitumoral effect of ...... xpressing breast cancer cells.
@nl
prefLabel
Synergic antitumoral effect of ...... xpressing breast cancer cells.
@en
Synergic antitumoral effect of ...... xpressing breast cancer cells.
@nl
P2860
P50
P356
P1433
P1476
Synergic antitumoral effect of ...... expressing breast cancer cells
@en
P2093
A Pandiella
L Ferreira
P2860
P304
P356
10.1093/ANNONC/MDN406
P577
2008-07-17T00:00:00Z